NCT04665661

Brief Summary

Primary dysmenorrhea is common and can result in significant disability for many women, causing a high degree of discomfort and reduced quality of life (QoL). Our preliminary studies suggested that high-intensity aerobic training (HIAT) for 30 minutes, three times a week at 70%-85% of maximum heart rate was effective for decreasing pain and improving QoL in women suffering from primary dysmenorrhea. However, to date, no studies have evaluated the beneficial effects of HIAT on academic performance and absenteeism or the cost-effectiveness of HIAT for women with primary dysmenorrhea. Furthermore, the mechanisms underlying aerobic exercise-induced analgesia in primary dysmenorrhea remain unclear. Here, we propose a study to address this important knowledge gap by investigating the effects of HIAT on absenteeism and academic performance among university students with primary dysmenorrhea and examine the physiological mechanisms underlying aerobic exercise-induced analgesia by conducting a fully powered, randomised, controlled crossover trial. We also propose to conduct an economic evaluation to determine the cost-effectiveness of HIAT compared with a wait-listed control group receiving usual care, according to the societal and healthcare perspectives of Hong Kong. The results of this cutting-edge research will be important for clinicians, researchers, policymakers, and women with primary dysmenorrhea. The knowledge gained from the proposed study will be useful for researchers when designing future studies to identify the mediators of pain interventions for clinical improvements, which could themselves be the target of future interventions. The findings of the proposed study will inform decision-makers regarding the extent to which existing or standard and potential interventions can improve population health (effectiveness) and the resources required to implement these interventions (costs).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
130

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2021

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2020

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 11, 2020

Completed
9 months until next milestone

Study Start

First participant enrolled

September 1, 2021

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2024

Completed
Last Updated

December 11, 2020

Status Verified

November 1, 2020

Enrollment Period

3 years

First QC Date

November 25, 2020

Last Update Submit

December 7, 2020

Conditions

Keywords

DysmenorrheaPrimary dysmenorrheaPainAbsenteeismAcademic performance

Outcome Measures

Primary Outcomes (15)

  • Pain intensity

    Average pain intensity during the last 24 hours during menstruation will be assessed using the 0-10 Numeric Rating Scale, with 0 representing 'No pain' and 10 representing 'Worst imaginable pain'. Higher scores indicate greater pain severity

    Pre-intervention (baseline, 0 week)

  • Pain intensity

    Average pain intensity during the last 24 hours during menstruation will be assessed using the 0-10 Numeric Rating Scale, with 0 representing 'No pain' and 10 representing 'Worst imaginable pain'. Higher scores indicate greater pain severity

    Post-intervention at 12 weeks

  • Pain intensity

    Average pain intensity during the last 24 hours during menstruation will be assessed using the 0-10 Numeric Rating Scale, with 0 representing 'No pain' and 10 representing 'Worst imaginable pain'. Higher scores indicate greater pain severity

    Post-intervention at 28 weeks

  • Absenteeism from university

    A prospective electronic diary will be provided for each participant to record university absenteeism.

    Pre-intervention (baseline, 0 week)

  • Absenteeism from university

    A prospective electronic diary will be provided for each participant to record university absenteeism.

    Post-intervention at 12 weeks

  • Absenteeism from university

    A prospective electronic diary will be provided for each participant to record university absenteeism.

    Post-intervention at 28 weeks

  • Academic performance

    Academic performance will be measured using the self-reported 20-item academic performance questionnaire, which was developed to measure the impacts of menstrual symptoms on academic performance. Greater scores indicate greater severity of primary dysmenorrhea

    Pre-intervention (baseline, 0 week)

  • Academic performance

    Academic performance will be measured using the self-reported 20-item academic performance questionnaire, which was developed to measure the impacts of menstrual symptoms on academic performance. Greater scores indicate greater severity of primary dysmenorrhea

    Post-intervention at 12 weeks

  • Academic performance

    Academic performance will be measured using the self-reported 20-item academic performance questionnaire, which was developed to measure the impacts of menstrual symptoms on academic performance. Greater scores indicate greater severity of primary dysmenorrhea

    Post-intervention at 28 weeks

  • Progesterone levels

    Salivary levels of progesterone.

    Pre-intervention (baseline, 0 week)

  • Progesterone levels

    Salivary levels of progesterone.

    Post-intervention at 12 weeks

  • Progesterone levels

    Salivary levels of progesterone.

    Post-intervention at 28 weeks

  • Prostaglandin F2-alpha levels

    Salivary levels of prostaglandin F2-alpha

    Pre-intervention (baseline, 0 week)

  • Prostaglandin F2-alpha levels

    Salivary levels of prostaglandin F2-alpha

    Post-intervention at 12 weeks

  • Prostaglandin F2-alpha levels

    Salivary levels of prostaglandin F2-alpha

    Post-intervention at 28 weeks

Secondary Outcomes (8)

  • Concentration

    Pre-intervention (baseline, 0 week)

  • Concentration

    Post-intervention at 12 weeks

  • Concentration

    Post-intervention at 28 weeks

  • Dysmenorrhea daily diary

    Pre-intervention (baseline, 0 week)

  • Dysmenorrhea daily diary

    Post-intervention at 12 weeks

  • +3 more secondary outcomes

Study Arms (2)

High-intensity aerobic training (HIAT)

EXPERIMENTAL

Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).

Behavioral: High-intensity aerobic trainingBehavioral: Wait-list control

Wait-list control (WLC)

ACTIVE COMPARATOR

Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).

Behavioral: High-intensity aerobic trainingBehavioral: Wait-list control

Interventions

Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).

High-intensity aerobic training (HIAT)Wait-list control (WLC)

Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).

High-intensity aerobic training (HIAT)Wait-list control (WLC)

Eligibility Criteria

Age18 Years - 24 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsParticipant eligibility is based on self-representation of gender identity as female
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • women in the age group of 18-24 years old;
  • non-pregnant;
  • having regular menstrual cycles with cycle lengths between 24 and 30 days;
  • experiencing an average menstrual pain intensity equal to or greater than 5 on a 0-10 Numerical Rating Scale; and
  • scoring low (\< 600 metabolic equivalent tasks \[MET\]/week) on the short-form of the International Physical Activity Questionnaire.

You may not qualify if:

  • women using oral contraceptive pills, hormonal therapy, or intrauterine devices;
  • women using over-the counter analgesics during menstruation to treat dysmenorrhea-associated pain and experience no pain relief with those analgesics; and
  • women participating in any formal exercise programme

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

DysmenorrheaPain

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and SymptomsPelvic PainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Priya Kannan, PhD

    The Hong Kong Polytechnic Unviersity

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Priya Kannan, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 25, 2020

First Posted

December 11, 2020

Study Start

September 1, 2021

Primary Completion

August 31, 2024

Study Completion

August 31, 2024

Last Updated

December 11, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share